Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer
-
Published:2018-02-20
Issue:6
Volume:36
Page:581-590
-
ISSN:0732-183X
-
Container-title:Journal of Clinical Oncology
-
language:en
-
Short-container-title:JCO
Author:
Spratt Daniel E.1, Zhang Jingbin1, Santiago-Jiménez María1, Dess Robert T.1, Davis John W.1, Den Robert B.1, Dicker Adam P.1, Kane Christopher J.1, Pollack Alan1, Stoyanova Radka1, Abdollah Firas1, Ross Ashley E.1, Cole Adam1, Uchio Edward1, Randall Josh M.1, Nguyen Hao1, Zhao Shuang G.1, Mehra Rohit1, Glass Andrew G.1, Lam Lucia L.C.1, Chelliserry Jijumon1, du Plessis Marguerite1, Choeurng Voleak1, Aranes Maria1, Kolisnik Tyler1, Margrave Jennifer1, Alter Jason1, Jordan Jennifer1, Buerki Christine1, Yousefi Kasra1, Haddad Zaid1, Davicioni Elai1, Trabulsi Edouard J.1, Loeb Stacy1, Tewari Ashutosh1, Carroll Peter R.1, Weinmann Sheila1, Schaeffer Edward M.1, Klein Eric A.1, Karnes R. Jeffrey1, Feng Felix Y.1, Nguyen Paul L.1
Affiliation:
1. Daniel E. Spratt, Robert T. Dess, Adam Cole, Shuang G. Zhao, and Rohit Mehra, University of Michigan, Ann Arbor; Firas Abdollah, Henry Ford Health System, Detroit, MI; Jingbin Zhang, María Santiago-Jiménez, Lucia L.C. Lam, Jijumon Chelliserry, Marguerite du Plessis, Voleak Choeurng, Maria Aranes, Tyler Kolisnik, Jennifer Margrave, Jason Alter, Jennifer Jordan, Christine Buerki, Kasra Yousefi, Zaid Haddad, and Elai Davicioni, GenomeDx Biosciences, Vancouver, British Columbia, Canada; John W. Davis, The...
Abstract
Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized prostate cancer. Materials and Methods Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups. Results With a median follow-up of 8 years for patients in the training cohort, 10-year distant metastasis rates for National Comprehensive Cancer Network (NCCN) low, favorable-intermediate, unfavorable-intermediate, and high-risk were 7.3%, 9.2%, 38.0%, and 39.5%, respectively. In contrast, the three-tier clinical-genomic risk groups had 10-year distant metastasis rates of 3.5%, 29.4%, and 54.6%, for low-, intermediate-, and high-risk, respectively, which were consistent in the validation cohort (0%, 25.9%, and 55.2%, respectively). C-indices for the clinical-genomic risk grouping system (0.84; 95% CI, 0.61 to 0.93) were improved over NCCN (0.73; 95% CI, 0.60 to 0.86) and Cancer of the Prostate Risk Assessment (0.74; 95% CI, 0.65 to 0.84), and 30% of patients using NCCN low/intermediate/high would be reclassified by the new three-tier system and 67% of patients would be reclassified from NCCN six-tier (very-low– to very-high–risk) by the new six-tier system. Conclusion A commercially available genomic classifier in combination with standard clinicopathologic variables can generate a simple-to-use clinical-genomic risk grouping that more accurately identifies patients at low, intermediate, and high risk for metastasis and can be easily incorporated into current guidelines to better risk-stratify patients.
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Cited by
163 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|